Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDO-Guided Targeted Therapy for Refractory HER2+ Breast Cancer
NCT05429684Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2021
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab, pertuzumab, pyrotinib, trastuzumab emtansine, everolimus in HER2-positive breast cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Status: unknown.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05429684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429684.